Daisuke Harada
Okayama University
15 Papers
22 Citations
Daisuke Harada is an academic researcher from Okayama University. The author has contributed to research in topics: Achondroplasia & Fibroblast growth factor receptor 3. The author has an hindex of 8, co-authored 15 publications.
Chat about Author
Papers
FGFR3-related dwarfism and cell signaling
TL;DR: Skeletal development consists of the following steps: skeletal patterning, mesenchymal differentiation, bone growth, and homeostasis, and Disorders of each bone formation step cause characteristic skeletal dysplasias.
46
Final adult height in long-term growth hormone-treated achondroplasia patients
Daisuke Harada,Noriyuki Namba,Yuki Hanioka,Kaoru Ueyama,Natsuko Sakamoto,Yukako Nakano,Masafumi Izui,Yuiko Nagamatsu,Hiroko Kashiwagi,Miho Yamamuro,Yoshihito Ishiura,Ayako Ogitani,Yoshiki Seino +12 more
TL;DR: Long-term GH treatment contributes to 2.6 and 2.1% of final adult height in male and female ACH patients, respectively.
Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLCγ-activated STAT1
Daisuke Harada,Yoshitaka Yamanaka,Koso Ueda,Riko Nishimura,Tsuneo Morishima,Yoshiki Seino,Hiroyuki Tanaka +6 more
TL;DR: It is concluded that sustained phosphorylation ofFGFR3 causes chondrodysplasia, and the phenotypic severity depends on the proportion of ER-localized mutant FGFR3.
32
Pyridoxal 5'-phosphate and related metabolites in hypophosphatasia: Effects of enzyme replacement therapy
Tomoyuki Akiyama,Takuo Kubota,Keiichi Ozono,Toshimi Michigami,Daisuke Kobayashi,Shinji Takeyari,Yuichiro Sugiyama,Masahiro Noda,Daisuke Harada,Noriyuki Namba,Atsushi Suzuki,Maiko Utoyama,Sachiko Kitanaka,Mitsugu Uematsu,Yusuke Mitani,Kunihiro Matsunami,Shigeru Takishima,Erika Ogawa,Katsuhiro Kobayashi +18 more
TL;DR: The serumPLP-to-PL ratio is a better indicator of the effect of ERT for HPP than serum PLP and urine PEA concentrations, and a PLP/PL ratio of <4.0 is a good indicator ofThe effect of, and patient compliance with, ERT.
20
A case of autosomal dominant osteopetrosis type II with a novel TCIRG1 gene mutation.
Keiko Wada,Daisuke Harada,Toshimi Michigami,Kanako Tachikawa,Yukako Nakano,Hiroko Kashiwagi,Sumie Yamashita,Tetsuya Sano,Yoshiki Seino +8 more
TL;DR: The case of a 3-year-old boy diagnosed as ADO implies that TCIRG1 could become a genetic candidate for ADO in addition to malignant forms such as ARO.
15